引言

循环血细胞通过造血过程在骨髓中形成。骨髓有强大的细胞生成能力，估计在稳态下每小时可生成1010个红细胞和108-109个白细胞。此外，虽然细胞数量维持在相当窄的范围内，但在需要时可大幅增加。

这些数量巨大的细胞是由源于数量较少祖细胞的成熟前体细胞直接生成。而祖细胞源于数量更少的造血干细胞(hematopoietic stem cell, HSC)，**目前认为HSC大多处于静止或不分裂状态，它们具有自我更新能力，因此可以维持自身数量。**

HSC为多能干细胞，可分化为所有10种血系的细胞：红细胞、血小板、中性粒细胞、嗜酸性粒细胞、嗜碱性粒细胞、单核细胞、T和B淋巴细胞、自然杀伤细胞和树突状细胞([图 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F52024&topicKey=HEME%2F3536&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&rank=1%7E150&source=see_link))[[1-3](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/1-3)]。

本专题将总结造血功能和HSC的调控。其他类型干细胞(包括诱导多能干细胞)的一般讨论参见其他专题。(参见 [“干细胞综述”](https://www.uptodate.cn/contents/zh-Hans/overview-of-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link))

骨髓解剖和微环境

造血部位 — 儿童的相对红髓腔(有造血活性)比成人大得多，可能是因为新生儿期需要生成大量红细胞。**虽然一些部位终身都有造血功能，包括椎骨、胸骨和胸骨柄、盆骨及长骨干骺端，但出生后红细胞需求减少，因此生成量也减少，很大一部分骨髓腔都逐渐缓慢充满脂肪，尤其是面骨及长骨(如桡骨、尺骨、股骨和腓骨)骨干的骨髓**[[4](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/4)]。如果患者有某些通常会引起贫血的疾病，如原发性骨髓纤维化、骨髓浸润性疾病(如肉芽肿或转移癌)或以无效红细胞生成为特征的疾病(如重型地中海贫血)，肝、脾和淋巴结可能恢复造血功能，肾上腺、软骨、脂肪组织、胸椎旁沟甚至肾脏也可能有造血功能。

骨髓微环境 — 造血祖细胞的发育和分化需要细胞成分和可溶性生长因子的支持，前者由周围的骨骼、骨髓基质([图 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F94175&topicKey=HEME%2F3536&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&rank=1%7E150&source=see_link))和微环境提供[[5-9](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/5-9)]。

骨髓腔的微环境是由血管(微动脉和引流至中央静脉的血窦)组成的巨大网状结构，其中悬浮着造血细胞，包括脂肪细胞。网状细胞构成血管窦的外膜表面，其胞质外突形成一种格子状结构，上面可见红细胞。通过骨髓片网硬蛋白染色可显示格子状结构，而采用扫描电子显微镜可发现网硬蛋白网的结构以及血管窦网状结构中造血细胞的位置。

提供细胞间接触的基质细胞网支持HSC和祖细胞。**基质细胞网主要有2种功能：为正在发育的细胞提供可附着的黏附结构架；生成必需的造血生长因子[[10](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/10)]。这些细胞和T淋巴细胞可产生多种黏附分子和造血生长因子或细胞因子，它们支持HSC和祖细胞的生存、增殖和分化。目前认为原始间充质基质细胞(mesenchymal stromal cell, MSC)可分化为骨系细胞(osteolineage cell)、软骨细胞、脂肪细胞和血管周细胞(称为CAR细胞或CXCL12网状细胞)，已从中检测到CXCL12、巢蛋白和瘦素受体(leptin receptor, LEPR)的表达。**

骨髓循环包括中央动脉和辐射状动脉，这些动脉分支形成皮质毛细血管、连接骨髓血窦并汇入中央窦。细胞通过伴行静脉离开骨髓血窦进入静脉循环。血窦的内表面或管腔面衬有内皮细胞(endothelial cell, EC)，内皮细胞的胞质延伸相互重叠或交错。正在发育的造血细胞通过这种内皮细胞内衬中的间隙以及内皮细胞胞质孔隙进入血窦，从而进入体循环。

HSC见于两种不同的龛：骨内膜龛(endosteal niche)，其中HSC紧邻一群N-钙黏着蛋白阳性的梭形成骨细胞；血管龛(vascular niche)，内衬有血窦内皮细胞和MSC衍生物([图 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F94175&topicKey=HEME%2F3536&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&rank=1%7E150&source=see_link))。据推测，这些单独的解剖区域对干细胞功能有不同的支持作用，但其他数据表明，骨内膜龛发挥着间接作用，其通过骨样细胞系细胞分泌细胞因子和细胞外基质蛋白来影响血窦基质细胞的功能。对骨髓片中的CD150阳性、CD48阴性、CD41阴性和Lin阴性HSC进行荧光染色发现，大多数HSC紧邻血窦，与MSC接触[[11](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/11)]。将α-catulin-GFP作为干细胞标记物进行深部共聚焦成像发现，HSC多见于中央骨髓而非骨内膜表面附近，且这些细胞与LEPR及CXCL12阳性龛细胞接触，且紧邻窦血管[[12](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/12)]。总体而言，这些龛为造血提供了微环境，其中包括骨系细胞、破骨细胞、血窦内皮细胞、巨噬细胞、MSC(包括CAR细胞)和交感神经元的细胞接触和分泌功能以及细胞外基质。

此外，巢蛋白阳性基质细胞也支持造血，目前认为该细胞来自神经嵴：

●骨系细胞是粒细胞集落刺激因子(granulocyte colony-stimulating factor, G-CSF)介导的HSC动员所必需的[[13](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/13)]，对T和B淋巴细胞的发育也很重要[[14,15](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/14,15)]。

●CAR细胞消融会导致干细胞因子(stem cell factor, SCF)和CXCL12减少，淋巴系祖细胞和红系祖细胞的增殖也会减少[[16,17](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/16,17)]。

●内皮细胞可表达黏附分子(如E-选择素)并分泌旁分泌生长因子和细胞因子，这些细胞可通过生成Notch配体调节培养时HSC的扩增[[18](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/18)]。

●巨噬细胞(CD169阳性)可分泌抑癌蛋白M，进而刺激巢蛋白阳性细胞表达CXCL12；CXCL12与HSC上的CXCR4受体结合对HSC滞留于骨髓龛很重要[[19,20](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/19,20)]。

●骨髓的交感神经支配可调节骨髓释放HSC的昼夜周期。[去甲肾上腺素](https://www.uptodate.cn/contents/zh-Hans/92151?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link)释放信号通过β3肾上腺素能受体传递至MSC，导致CXCL12表达和HSC释放迅速下调[[21](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/21)]。

造血干细胞

HSC的特性 — 一系列实验都证实存在多能干细胞。研究发现，通过外置和屏蔽脾脏可防止全身照射导致小鼠死亡，因此研究者提出持续造血功能来自于多能干细胞[[22](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/22)]。这种保护作用是由细胞介导的，因为对接受照射的动物注射脾细胞可启动恢复过程并重建造血功能[[23](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/23)]。

研究证实，在移植后10日内，接受照射的移植受者的脾脏中会出现鼠造血细胞克隆，该结果与造血的克隆性假说以及单个多能干细胞可重建整个造血系统的观念相一致[[24](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/24)]。这些**脾集落形成单位(spleen colony-forming unit, CFU-S)生成包含红细胞、粒细胞、巨噬细胞和巨核细胞的前体细胞的集落。**

随后采用核型标记的供体细胞进行实验，证实了集落中分化细胞的克隆起源，表明单个多能HSC产生了这些分化细胞[[25](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/25)]。研究还发现，在移植后第12日形成的每个集落(CFU-S12)中都有很多细胞可在其他接受照射的鼠体内再次形成分化细胞集落，表明这些细胞具有自我更新能力，而在移植后第8日形成的脾集落(CFU-S8)只有分化为骨髓红系细胞的潜能。

研究证实成人骨髓中存在多能干细胞，因此人们对HSC的个体发育起源进行了系统研究。在哺乳动物中，造血作用依次发生于卵黄囊、胚胎内主动脉-性腺-中肾(aorta-gonad-mesonephros, AGM)区、胎盘、胎肝，最后为骨髓。关于HSC最先出现在卵黄囊还是AGM区，目前仍有争议。Metcalf和Moore进行的经典研究[[26](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/26)]表明，如果在第7.5日移除卵黄囊，则胎肝不会发生造血过程，且早至第9日就可在鼠卵黄囊中检测到HSC样细胞[[27](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/27)]。研究发现卵黄囊的造血过程分为两波，最初生成包含大细胞性有核细胞的原始红细胞(E7.25)；之后立即(E8.5)生成次级红系-髓系祖细胞(在循环建立后可转移至胎肝)，这可以解释上述结果。在妊娠期迅速发生红系扩增时，红系祖细胞的后代支持胎儿红细胞生成，髓系祖细胞可在脑(小胶质细胞)、皮肤和肝脏内生成存活期较长(成体)的定居巨噬细胞衍生物[[28,29](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/28,29)]。研究显示，具有长期重建HSC(即LT-HSC)活性的细胞最先出现在AGM区，而非卵黄囊或其他胚胎内区域，这一重要结果表明能够重建造血功能的HSC首先在胚体内形成[[30,31](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/30,31)]。

HSC所在部位 — 现已证实，人类和/或实验动物的循环中有多种早期造血细胞，包括多能干细胞和某些定向祖细胞[[32-35](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/32-35)]。

分娩后直接从胎盘获取的脐带血中也有HSC。与骨髓和外周循环相比，脐带血富含干细胞，且可用于干细胞移植。(参见 [“造血干细胞移植用脐带血的采集和储存”](https://www.uptodate.cn/contents/zh-Hans/collection-and-storage-of-umbilical-cord-blood-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link)和 [“造血干细胞的来源”，关于‘脐带血’一节](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?sectionName=%E8%84%90%E5%B8%A6%E8%A1%80&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&anchor=H63572418&source=see_link#H63572418))

目前认为，在出生后，大多数HSC主要位于骨髓。骨髓与血液中原始CD34+细胞的基因表达谱有显著差异，骨髓源性细胞的循环更快，而外周循环中的CD34+细胞包含更多静止干细胞和祖细胞[[36,37](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/36,37)]。这些差异比较有趣，可能表明这两个细胞群存在异质性，因为可重建造血功能的干细胞仅占这两种细胞群的一小部分。

干细胞和祖细胞的识别 — 有多种检测方法可识别干细胞。调控干细胞生成的因子尚未完全确定，但包括各种体液或骨髓基质源性调控因子。

显微镜下可识别成熟前体细胞与成熟细胞。而通过形态无法区分祖细胞与HSC，需要进行功能分析或识别表面抗原特征来检测这两种细胞。如果将祖细胞固定在半固体培养基，如含甲基纤维素或琼脂的半固体培养基，并使用生长因子进行刺激，其可形成不同谱系的成熟细胞集落，通常统称为集落形成细胞(colony forming cell, CFC)或集落形成单位(colony forming unit, CFU)。生长因子包括([表 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F57050&topicKey=HEME%2F3536&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&rank=1%7E150&source=see_link))：

●SCF(也称为Steel因子或KIT配体)[[38](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/38)]、IL-3、粒细胞-巨噬细胞集落刺激因子(granulocyte-macrophage colony-stimulating factor, GM-CSF)和促红细胞生成素(erythropoietin, EPO)驱动原始爆式红系集落形成单位(erythroid burst-forming unit, BFU-E)增殖和成熟；成熟度更高的红系CFU(erythroid colony-forming unit, CFU-E)最初几次分裂完全依赖于EPO。

●SCF、G-CSF和GM-CSF驱动粒-巨噬细胞CFU(granulocyte and macrophage colony-forming unit, CFU-GM)形成。

体外测定 — 有人提出用多种测定HSC功能特征的体外检测代替HSC检测，但如果不能同时采用体外和体内移植试验来评估同质人群，可能无法确定这些方法测定的精确细胞类型。采用甲基纤维素半固体培养基培养人骨髓，最终形成包含粒细胞、红细胞、单核细胞和巨核细胞的CFU(colony-forming unit that contain granulocytes, erythrocytes, monocytes and megakaryocytes, CFU-GEMM)，可证实多能性[[32,39-41](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/32,39-41)]。现已报道了一种含有少量原始细胞且自我更新能力(再次接种时形成二级集落)比CFU-GEMM强的独特体外原始细胞集落[[42](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/42)]。

支持存在多能HSC的证据也来自人类骨髓液体培养技术“Dexter”培养体系[[43](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/43)]，采用这种培养体系时，髓系祖细胞(主要为CFU-GM)可在贴壁基质单层上和单层内持续约2个月[[44,45](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/44,45)]。在5-8周时再接种到含有几种生长因子的甲基纤维素培养基中，可检测到祖细胞，这证实在“Dexter”培养体系中可产生单能细胞和多能细胞。

这种长期培养技术也可用于有限稀释法，即将不同浓度的细胞接种到基质层，培养5周后再接种到甲基纤维素培养基，以确定不含集落的孔数，从而可确定长期培养启动细胞(long-term culture initiating cell, LTC-IC)的数量[[46](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/46)]。一种类似的鹅卵石样区域形成细胞(cobblestone area-forming cell, CAFC)测定也可用于人类细胞，这种方法直接计数基质层中的增殖克隆[[47](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/47)]；活跃造血区呈“鹅卵石样”。最后，高增殖潜能CFC(high proliferative potential colony forming cell, HPP-CFC)试验可测定原始祖细胞的强大增殖能力，该试验可形成肉眼可见(>5mm)的集落[[48,49](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/48,49)]。

虽然这些体外试验可测定HSC的多能性或高增殖特性，但无法检测HSC重建长期造血功能的本质特性。该特性最好通过体内移植试验来确定。现已在小鼠中开发了一种竞争性重建试验来测定鼠HSC的数量，该试验将未知干细胞群与标准量竞争细胞共同植入受到照射的小鼠体内[[50](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/50)]。此外，可将人类HSC注入严重联合免疫缺陷病(severe combined immunodeficient, SCID)或非肥胖型糖尿病(nonobese diabetic, NOD)/SCID小鼠体内，随后监测6-8周，确定人类HSC是否在小鼠骨髓中植活[[51](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/51)]。

这种SCID再植细胞(SCID repopulating cell, SRC)比体外试验测定的细胞更接近HSC[[51](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/51)]。这些不同的干细胞和祖细胞检测方法所测定细胞的初步关系见图。

细胞表面抗原标志物 — 细胞表面特征可用于纯化或界定包括HSC和祖细胞在内的细胞群。人类中最常用的标志物为CD34抗原和CD38，前者在HSC和祖细胞中表达，后者在成熟度更高的祖细胞和成熟细胞中表达，但**不**在HSC中表达。

最原始的人类造血细胞为CD34+和CD38-[[52-54](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/52-54)]。不过，CD34+细胞占骨髓中有核细胞的2%-5%，而HSC要罕见得多，在骨髓细胞中的比例约为1/20,000。因此，虽然CD34等标志物有助于富集原始细胞，但它们只是存在HSC的间接指标。

联合HSC表达的其他细胞表面蛋白质(如CD133、KIT或CD150)的抗体，同时去除表达谱系标志物的细胞(Lin-)，可更大程度地富集LT-HSC[[55-57](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/55-57)]。NOD/SCID小鼠模型研究发现，小鼠骨髓可通过表达FLT3的CD34+/CD38-/lin-细胞呈现人类造血过程[[58](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/58)]。输注FLT3阴性的类似细胞不能成功植活。

其他用于界定HSC群的细胞特征包括能够排出活体染料，如罗丹明123(Rh-123淡染)和Hoechst 33342(侧群细胞)，以及乙醛脱氢酶活性[[59-61](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/59-61)]。

采用KIT+/lin-细胞或Hoechst染色的实验表明，具有长期重建能力的鼠类、灵长类和人类HSC可能属于CD34-细胞群[[62-64](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/62-64)]。但由于实验和移植数据表明HSC确实会表达CD34，这一点尚有争议[[65-69](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/65-69)]。另外2项研究发现了支持性证据，即通过单克隆抗体分离的CD34-细胞，在免疫缺陷动物中有植活潜能和骨髓重建能力[[70,71](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/70,71)]。然而，这些研究对人类HSC移植的意义取决于发现这些细胞的阳性筛选标志物，以及证实这些细胞可以重建人类骨髓[[64](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/64)]。

现已通过纯化将高度富集的人类HSC移植到免疫缺陷小鼠体内，这种纯化利用了一组不同的标志物：CD34+、CD38-、CD45RA-、CD90+(Thy1+)和CD49f+，并在这些细胞的Rho-细胞群中进一步富集(单细胞植活能力)[[72,73](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/72,73)]。在小鼠中，目前最先进的HSC纯化方法包括以下标志物：CD34-、CD150+、CD48-、CD41-、flt3-和CD49b lo[[56,74](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/56,74)]。

HSC异质性 — 造血细胞移植研究发现了一种干细胞室(stem cell compartment)模型，即干细胞室由连续发育过程不同阶段的细胞组成，这些细胞的自我更新能力不断降低、分化可能性逐渐增加且增殖活性不断增强，它们呈单向发展[[75,76](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/75,76)]。

最原始的HSC细胞具有最强的自我更新能力，在移植到受照射的小鼠体内后可长期重建造血功能。这些细胞称为LT-HSC，可从短期HSC(short-term hematopoietic stem cell, ST-HSC)和分化潜能逐渐受限的各系定向祖细胞中分离。

然而，基于表面抗原表达(Thy-1.1低表达、Lin-、Sca-1+)和Rh-123-淡染对鼠HSC进行纯化发现，少至5个细胞即可长期重建造血功能，但该细胞群仍然存在异质性，因为它包括仅有LT-HSC活性的细胞和同时具有LT-HSC和ST-HSC潜能的细胞[[77](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/77)]。大多数有短期辐射防护能力的细胞都可能表达相同的细胞表面抗原(Thy-1.1低表达、Lin-、Sca-1+)，但Rh-123染色更亮[[78,79](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/78,79)]。

使用逆转录病毒标记的HSC进行移植研究发现，长期存在相对较少的可多系分化的克隆。但移植需要清髓，且很可能诱导移植HSC应激。一些实验采用称为“条形码”的独特基因标志物，并用转座子标记体内的多种造血细胞，发现了稳态非应激性造血；纵向分析表明，造血功能由成千上万的克隆维持，其中很多都有ST-HSC和祖细胞的特性[[80](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/80)]。用Tie2Cre标记胚胎发育过程中最原始的HSC来追踪LT-HSC的命运，也发现ST-HSC对稳态造血的作用比LT-HSC显著，且稳定状态下大约只有30%的LT-HSC可产生细胞[[81](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/81)]。

传统分化等级模型是从LT-HSC分化为多能共同髓系祖细胞(common myeloid progenitor, CMP)和共同淋巴样祖细胞(common lymphoid progenitor, CLP)，CMP又分为巨核系-红系祖细胞(megakaryocyte erythroid progenitor, MEP)和粒细胞/单核祖细胞(granulocyte/monocyte progenitor, GMP)，但该模型受到了质疑。采用其他标记物分析这些多能祖细胞发现，每种细胞群都有异质性。采用多种细胞因子培养后进行单细胞分类和后代细胞分析发现，在胎儿发育期间，巨核细胞和红系定向发生于分化的多能、寡能和单能阶段，而髓系祖细胞和淋巴系/单核祖细胞仅出现在后两个阶段。而成人骨髓以单系祖细胞为主，主要具有髓系和红系潜能[[82](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/82)]。

干细胞调控

调节分子 — 大多数调节分子由紧邻祖细胞的造血辅助细胞产生。这些分子是复杂造血调控网络的一部分，该网络尚未完全明确，其近距离发挥作用，可能涉及造血辅助细胞-祖细胞的相互作用。**SCF和FLT3配体(FLT3 ligand, FLT3L)均是受体酪氨酸激酶的配体，会与多种造血祖细胞相互作用，或许最重要的是与极早期干细胞群相互作用。这两种因子均有膜结合型和可溶型，膜结合型在骨髓微环境中的近距离相互作用方面发挥着重要作用。**

其他会影响HSC造血的SCF包括Wnt、Jagged、骨形成蛋白(bone morphogenic protein, BMP)和血管生成素样生长因子。

●Wnt信号通过经典途径(β-连环蛋白)和非经典途径传递。Wnt3A过表达会引起HSC池增大，而组成性激活的β-连环蛋白可导致再生障碍性贫血[[83,84](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/83,84)]。经典途径参与HSC的活化，而非经典途径参与HSC的静止，这些不同的作用可协调上述差异[[85](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/85)]。

●Jagged2似乎是成骨细胞表达的主要Notch配体，在斑马鱼系统中通过Runx1使HSC扩增。

●在斑马鱼和非洲爪蟾系统中，BMP会诱导HSC生成。

●血管生成素也可扩大HSC群[[86](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/86)]。

●骨桥蛋白和转化生长因子-β(transforming growth factor beta, TGF-β)等其他生长因子是负调控因子，可能对维持干细胞的静止状态十分重要。

自我更新 vs 分化 — 脊椎动物(包括人类)体内的血液成分会不断更新，以维持恒定数量的红细胞、白细胞和血小板。普通成人体内每种细胞的数量维持在较窄范围内，全血中粒细胞、红细胞和血小板的含量分别约为5000/μL，5x106/μL和150,000-300,000/μL。目前尚未完全明确维持新生血细胞生成平衡的调节机制，但现有证据强烈支持以下基本原则([图 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F52024&topicKey=HEME%2F3536&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&rank=1%7E150&source=see_link))：

●单个多能干细胞可通过克隆增殖产生很多定向祖细胞、特定类型血细胞的分化可识别前体细胞以及成熟细胞。此外，大多数多能干细胞都处于静止状态，仅少量活化干细胞的后代似乎就能维持造血稳态。“克隆演变”假说认为，一系列干细胞可能相继提供克隆以在整个生命过程中维持造血，这种假说很好地解释了“活化”和“静止”干细胞克隆的存在，有实验证据强烈支持该假说但并不明确[[87](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/87)]。体内溴脱氧尿嘧啶核苷标记数据表明，每日约有8%的鼠干细胞进入细胞周期[[88](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/88)]，这进一步支持干细胞定期从静止状态转变为活化状态的可能性。

●多能干细胞能自我更新，但这种特性可能不是无限的[[77,89,90](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/77,89,90)]。HSC的自我更新潜能有限，取决于复制史[[91,92](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/91,92)]，还可能取决于累积的DNA损伤[[93](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/93)]。定向祖细胞的增殖潜能有限，还会“因分化而死亡”，其数量取决于来自多能干细胞池的流入量[[94](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/94)]。

●定向祖细胞可对体液或骨髓基质来源的调节因子产生应答，一些调节因子是由于机体对循环中特定类型分化细胞的水平产生应答而生成(参见 [“红细胞生成的调控”](https://www.uptodate.cn/contents/zh-Hans/regulation-of-erythropoiesis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link)和 [“骨髓细胞生成的调节”](https://www.uptodate.cn/contents/zh-Hans/regulation-of-myelopoiesis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link))。在这种应答中，祖细胞增殖并分化形成可识别的血细胞。在这种控制下，血细胞生成增加发生在定向祖细胞水平。有证据表明定向祖细胞能自我更新。例如，糖皮质激素会使BFU-E数量增加[[95](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/95)]，这可能是应激过程中红细胞生成快速增加的基础。

关于干细胞选择自我更新还是分化(即谱系定向)的影响机制，现已提出了两种模型。一种模型认为自我更新或分化随机发生，仅由一定概率决定[[94,96](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/94,96)]。而另一个模型认为造血微环境是诱导性的，其依据为研究发现单个脾集落中存在特定谱系的区域[[97](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/97)]。该模型中，造血诱导微环境(hematopoietic inductivemicroenvironment, HIM)可决定干细胞的命运。然而，集落中某种分化细胞占优势的情况似乎由影响细胞成熟而非谱系定向的事件导致。

现有大量证据支持谱系定向和分化潜能限制的随机模型[[98-100](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/98-100)]。这种模型认为，**一些核转录因子组合对来自间充质细胞的干细胞特异化和早期干细胞增殖有一定作用，而其他独特的转录因子组合可能随机激活。由于这些转录因子决定谱系特异性蛋白质的合成，如细胞表面生长因子受体，它们是不同细胞系发育所必需的**[[101-103](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/101-103)]。目前仍不确定外部因素(如白细胞减少或贫血)对干细胞水平调节的可能作用[[104,105](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/104,105)]。

造血过程中转录因子及其调控的关键基因的表达取决于周围DNA的状态，还可能受表观遗传学改变(如，不涉及序列改变的DNA和染色质变异)的影响[[106](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/106)]。CpG二核苷酸中胞嘧啶甲基化与转录阻遏有关，而未甲基化的CpG岛见于活跃转录的启动子。组蛋白尾端的多种翻译后修饰与远端增强子和启动子的激活和阻遏有关。DNA甲基化和组蛋白修饰的改变对HSC自我更新和分化的调节很重要，对随着胎儿发育和干细胞老化发生的发育改变也很重要[[107,108](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/107,108)]。**DNA甲基转移酶Dnmt3a对HSC自我更新基因的沉默(从而能够分化)至关重要[[109](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/109)]，组蛋白脱甲基酶(如Lsd1和Jarid1b)具有相似作用**[[110,111](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/110,111)]。

HSC和干细胞微环境在老化、炎症和髓系恶性肿瘤中的作用 — 小鼠模型中的细胞老化特征显示，干细胞池扩大，且干细胞归巢和重建能力减弱、贫血和偏向于髓系分化。

细胞内在的缺陷包括：

●基因组不稳定导致年龄相关克隆性造血(age-related clonal hematopoiesis, ARCH)和代谢失控。**虽然正常的静止HSC依赖于糖酵解，但在活化和分化过程中，HSC的代谢会转变为氧化磷酸化和产生活性氧。老化的HSC显示，从静止转变为活化状态，且分化和干细胞重建能力减弱。**

●**这些改变与表观遗传学改变有关，后者涉及sirtuin蛋白、组蛋白乙酰基转移酶、双加氧酶[如，Tet甲基胞嘧啶双加氧酶2(Tet methylcytosine dioxygenase 2, TET2)[[112](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/112)]]，以及DNA甲基转移酶3α(DNA methyltransferase 3 alpha, DNMT3A)。需注意，小鼠失去Dnmt3a会使HSC发生永生化**[[113,114](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/113,114)]。细胞外在的老化缺陷是：失去对维持静止HSC十分重要的骨内膜成骨细胞、骨祖细胞和交感神经。

●血窦内皮细胞和MSC显示，HSC支持因子表达下调，如SCF、CXCL12和ANGPT1[[115](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/115)]。应注意，年轻的内皮细胞可在体外和体内使衰老的HSC年轻化[[116](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/116)]。

在感染或组织损伤时急性炎症信号的作用下，HSC会失去静止性，对细胞因子和Toll样受体(Toll-like receptor, TLR)配体产生应答而短暂增殖。内皮细胞会上调TLR4和髓系分化初级应答蛋白88(MyD88)，随后分泌G-CSF，引起紧急粒细胞生成。单细胞RNA研究显示，失去内皮细胞表达的Notch配体DLL4会引起HSC偏向于骨髓细胞生成[[117](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/117)]。然而，长期炎症暴露可能有害，导致干细胞减少甚至耗竭[[118](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/118)]。IFN-γ等干扰素可调节HSC对STAT1等细胞因子的应答，从而影响HSC自我更新和重建功能[[119](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/119)]。

损害HSC龛的细胞还可能诱导不可逆性HSC改变。关于视网膜母细胞瘤(retinoblastoma, RB)蛋白或视黄酸受体γ(retinoic acid receptor gamma, RARγ)缺乏的小鼠模型研究首次发现了这种令人惊讶的机制。将野生型HSC植入这些小鼠会导致供体细胞发生骨髓增生异常，该结果令人意外[[120,121](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/120,121)]。随后的研究发现，去除骨祖细胞中的微小RNA加工酶Dicer会导致骨髓增生异常和急性髓系白血病(acute myeloid leukemia, AML)。去除Dicer酶会减少_SBDS_基因的表达，遗传性骨髓衰竭病Shwachman-Diamond综合征(Shwachman Diamond syndrome, SDS)是由该基因突变引起[[122](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/122)]。SDS患者发生骨髓增生异常和AML的风险升高。其他研究表明，MSC中β-连环蛋白激活突变可通过HSC中的Jagged 1表达和Notch信号传递，导致骨髓增生异常综合征(myelodysplastic syndrome, MDS)和AML[[123](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/123)]。此外，Noonan综合征中的间充质前体细胞_PTPN11_基因突变会促发幼年型粒单核细胞白血病(juvenile myelomonocytic leukemia, JMML)样疾病，并导致移植后发生供体细胞源性骨髓增殖性肿瘤[[124](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/124)]。

一些综述阐述了骨髓微环境的这些引人注目的作用[[125-129](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/125-129)]。

HSC的治疗应用目前尚未明确人类体内是否存在具有自我更新多能干细胞特征的细胞。但在人类中采用骨髓、化疗和/或G-CSF动员的血液或脐带血作为干细胞来源时能够成功移植，据此可推测存在LT-HSC。(参见 [“造血干细胞移植的供者选择”](https://www.uptodate.cn/contents/zh-Hans/donor-selection-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link)和 [“造血干细胞的来源”](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link))

干细胞的主要治疗应用包括：

●对于存在骨髓衰竭或影响血细胞生成和功能的遗传性疾病的患者，可通过异基因干细胞移植重建造血。(参见 [“成人再生障碍性贫血的治疗”](https://www.uptodate.cn/contents/zh-Hans/treatment-of-aplastic-anemia-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link)和 [“造血细胞移植治疗成人再生障碍性贫血”](https://www.uptodate.cn/contents/zh-Hans/hematopoietic-cell-transplantation-for-aplastic-anemia-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link))

●对于可能获益于强化放化疗的恶性疾病(如AML)患者，可通过自体或异基因干细胞移植重建造血。(参见 [“年轻成人急性髓系白血病的缓解后治疗”](https://www.uptodate.cn/contents/zh-Hans/post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link)和 [“不适合强化治疗的急性髓系白血病成人的治疗”](https://www.uptodate.cn/contents/zh-Hans/acute-myeloid-leukemia-management-of-medically-unfit-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&source=see_link))

●将正常的基因拷贝或转录抑制因子插入有基因缺陷的干细胞中，之后将这些干细胞移植到患者体内，其可长期充分表达以纠正或缓解遗传疾病(即基因治疗)。目前该领域取得了重大进展，详见其他专题。(参见 [“Overview of gene therapy, gene editing, and gene silencing”, section on ‘Inherited single gene disorders’](https://www.uptodate.cn/contents/overview-of-gene-therapy-gene-editing-and-gene-silencing?sectionName=Inherited+single+gene+disorders&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&anchor=H1458528863&source=see_link#H1458528863)和 [“Overview of gene therapy, gene editing, and gene silencing”, section on ‘Clinical applications of gene silencing’](https://www.uptodate.cn/contents/overview-of-gene-therapy-gene-editing-and-gene-silencing?sectionName=Clinical+applications+of+gene+silencing&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3536&anchor=H1652566791&source=see_link#H1652566791))

目前很多研究的重点在于：识别最佳供体和干细胞来源(骨髓或血液)；纯化干细胞以消除肿瘤细胞污染、减少移植物抗宿主病以及优化基因转移；体外干细胞扩增以减少恶性细胞污染和/或成功植活所需的骨髓量。

大多数情况下，骨髓中LT-HSC生长似乎需要微环境“龛”[[1,130-132](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/1,130-132)]。因此，只有移植受体经过放疗或足量细胞毒药物治疗后建立足够数量的“龛”，同基因骨髓输注才会成功(参见上文[‘骨髓微环境’](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1531764))。但实验表明，如果植入非常多的干细胞，则不需要清髓[[133](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/133)]。

总结

●来自较大静止干细胞池、缓慢循环的少量多能干细胞可在整个生命过程中维持造血。干细胞可以自我更新或定向分化为各种造血谱系，这个过程是随机的，包括由多种转录因子介导的增殖和分化程序。(参见上文[‘造血干细胞’](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H3))

●有两种外在调控可能影响干细胞的调节。一个层面为基质细胞控制，基质细胞可能主要调控干细胞的生存，但也可能调节其对体液因子的应答。另一层面为体液生长因子，体液生长因子似乎会影响干细胞，但可能对定向成熟祖细胞和前体细胞的增殖和分化有更大影响。(参见上文[‘干细胞调控’](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H9))

使用UpToDate临床顾问须遵循[使用条款](https://www.uptodate.cn/legal/china/license).

参考文献

1.  [Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6:93.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/1)
2.  [Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood 2008; 111:492.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/2)
3.  [Metcalf D. Hematopoietic cytokines. Blood 2008; 111:485.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/3)
4.  Functions of the Blood, MacFarlane RC, Robb-Smith AHT (Eds), Blackwell Scientific, Oxford 1961. p.357.
5.  [Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005; 105:2631.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/5)
6.  [Wilson A, Trumpp A. Bone marrow haematopoietic-stem-cell niches. Nature Rev Stem Cells Collection 2008; Supplement:S5.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/6)
7.  [Papayannopoulou T, Scadden DT. Stem-cell ecology and stem cells in motion. Blood 2008; 111:3923.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/7)
8.  [Xie Y, Yin T, Wiegraebe W, et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 2009; 457:97.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/8)
9.  [Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012; 481:457.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/9)
10.  [Majumdar MK, Thiede MA, Mosca JD, et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998; 176:57.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/10)
11.  [Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature 2014; 505:327.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/11)
12.  [Acar M, Kocherlakota KS, Murphy MM, et al. Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature 2015; 526:126.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/12)
13.  [Ferraro F, Lymperi S, Méndez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011; 3:104ra101.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/13)
14.  [Greenbaum A, Hsu YM, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013; 495:227.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/14)
15.  [Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 2013; 495:231.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/15)
16.  [Omatsu Y, Sugiyama T, Kohara H, et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 2010; 33:387.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/16)
17.  [Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466:829.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/17)
18.  [Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010; 6:251.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/18)
19.  [Chow A, Lucas D, Hidalgo A, et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011; 208:261.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/19)
20.  [Albiero M, Poncina N, Ciciliot S, et al. Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M. Diabetes 2015; 64:2957.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/20)
21.  [Méndez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008; 452:442.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/21)
22.  [Jacobson LO, Marks EK, Gaston EO, et al. Role of the spleen in radiation injury. Proc Soc Exp Biol Med 1949; 70:7440.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/22)
23.  [FORD CE, HAMERTON JL, BARNES DW, LOUTIT JF. Cytological identification of radiation-chimaeras. Nature 1956; 177:452.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/23)
24.  [TILL JE, McCULLOCH EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14:213.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/24)
25.  [BECKER AJ, McCULLOCH EA, TILL JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963; 197:452.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/25)
26.  [Moore MA, Metcalf D. Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo. Br J Haematol 1970; 18:279.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/26)
27.  [Palis J, Yoder MC. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp Hematol 2001; 29:927.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/27)
28.  [Frame JM, McGrath KE, Palis J. Erythro-myeloid progenitors: "definitive" hematopoiesis in the conceptus prior to the emergence of hematopoietic stem cells. Blood Cells Mol Dis 2013; 51:220.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/28)
29.  [England SJ, McGrath KE, Frame JM, Palis J. Immature erythroblasts with extensive ex vivo self-renewal capacity emerge from the early mammalian fetus. Blood 2011; 117:2708.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/29)
30.  [Medvinsky AL, Samoylina NL, Müller AM, Dzierzak EA. An early pre-liver intraembryonic source of CFU-S in the developing mouse. Nature 1993; 364:64.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/30)
31.  [Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 1996; 86:897.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/31)
32.  [Fauser AA, Messner HA. Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood. Blood 1978; 52:1243.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/32)
33.  [Calvo W, Fliedner TM, Herbst E, et al. Regeneration of blood-forming organs after autologous leukocyte transfusion in lethally irradiated dogs. II. Distribution and cellularity of the marrow in irradiated and transfused animals. Blood 1976; 47:593.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/33)
34.  [Barr RD, Whang-Peng J, Perry S. Hemopoietic stem cells in human peripheral blood. Science 1975; 190:284.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/34)
35.  [Clarke BJ, Housman D. Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood. Proc Natl Acad Sci U S A 1977; 74:1105.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/35)
36.  [Steidl U, Kronenwett R, Rohr UP, et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 2002; 99:2037.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/36)
37.  [Terskikh AV, Miyamoto T, Chang C, et al. Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 2003; 102:94.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/37)
38.  [Corey SJ, Anderson SM. Src-related protein tyrosine kinases in hematopoiesis. Blood 1999; 93:1.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/38)
39.  [Fauser AA, Kanz L, Bross KJ, Löhr GW. T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. J Clin Invest 1985; 75:1080.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/39)
40.  [Fauser AA, Messner HA. Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neurtophilic granulocytes and erythroblasts. Blood 1979; 53:1023.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/40)
41.  [Leary AG, Ogawa M, Strauss LC, Civin CI. Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes. J Clin Invest 1984; 74:2193.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/41)
42.  [Nakahata T, Ogawa M. Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc Natl Acad Sci U S A 1982; 79:3843.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/42)
43.  [Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977; 91:335.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/43)
44.  [Coulombel L, Kalousek DK, Eaves CJ, et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308:1493.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/44)
45.  [Greenberg HM, Newburger PE, Parker LM, et al. Human granulocytes generated in continuous bone marrow culture are physiologically normal. Blood 1981; 58:724.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/45)
46.  [Sutherland HJ, Lansdorp PM, Henkelman DH, et al. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci U S A 1990; 87:3584.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/46)
47.  [Breems DA, Blokland EA, Neben S, Ploemacher RE. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 1994; 8:1095.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/47)
48.  [Bradley TR, Hodgson GS. Detection of primitive macrophage progenitor cells in mouse bone marrow. Blood 1979; 54:1446.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/48)
49.  [McNiece IK, Stewart FM, Deacon DM, et al. Detection of a human CFC with a high proliferative potential. Blood 1989; 74:609.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/49)
50.  [Szilvassy SJ, Humphries RK, Lansdorp PM, et al. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proc Natl Acad Sci U S A 1990; 87:8736.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/50)
51.  [Kamel-Reid S, Dick JE. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988; 242:1706.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/51)
52.  [Terstappen LW, Huang S, Safford M, et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991; 77:1218.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/52)
53.  [Sutherland HJ, Eaves CJ, Eaves AC, et al. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 1989; 74:1563.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/53)
54.  [Glimm H, Eisterer W, Lee K, et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. J Clin Invest 2001; 107:199.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/54)
55.  [Gunji Y, Nakamura M, Osawa H, et al. Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells. Blood 1993; 82:3283.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/55)
56.  [Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121:1109.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/56)
57.  [Ratajczak MZ, Pletcher CH, Marlicz W, et al. CD34+, kit+, rhodamine123(low) phenotype identifies a marrow cell population highly enriched for human hematopoietic stem cells. Leukemia 1998; 12:942.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/57)
58.  [Ebihara Y, Wada M, Ueda T, et al. Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34+CD38- cells expressing Flk2/Flt3. Br J Haematol 2002; 119:525.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/58)
59.  [Fallon P, Gentry T, Balber AE, et al. Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol 2003; 122:99.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/59)
60.  [McKenzie JL, Takenaka K, Gan OI, et al. Low rhodamine 123 retention identifies long-term human hematopoietic stem cells within the Lin-CD34+CD38- population. Blood 2007; 109:543.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/60)
61.  [Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183:1797.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/61)
62.  [Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273:242.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/62)
63.  [Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3:1337.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/63)
64.  [Nakauchi H. Hematopoietic stem cells: are they CD34-positive or CD34-negative? Nat Med 1998; 4:1009.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/64)
65.  [Civin CI, Almeida-Porada G, Lee MJ, et al. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 1996; 88:4102.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/65)
66.  [Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A 1992; 89:2804.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/66)
67.  [Srour EF, Zanjani ED, Cornetta K, et al. Persistence of human multilineage, self-renewing lymphohematopoietic stem cells in chimeric sheep. Blood 1993; 82:3333.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/67)
68.  [Berenson RJ, Bensinger WI, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77:1717.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/68)
69.  [Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85:3048.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/69)
70.  [Zanjani ED, Almeida-Porada G, Livingston AG, et al. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol 1998; 26:353.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/70)
71.  [Bhatia M, Bonnet D, Murdoch B, et al. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 1998; 4:1038.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/71)
72.  [Notta F, Doulatov S, Laurenti E, et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011; 333:218.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/72)
73.  [Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell 2012; 10:120.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/73)
74.  [Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241:58.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/74)
75.  [Hellman S, Botnick LE, Hannon EC, Vigneulle RM. Proliferative capacity of murine hematopoietic stem cells. Proc Natl Acad Sci U S A 1978; 75:490.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/75)
76.  [Ma F, Wada M, Yoshino H, et al. Development of human lymphohematopoietic stem and progenitor cells defined by expression of CD34 and CD81. Blood 2001; 97:3755.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/76)
77.  [Spangrude GJ, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood 1995; 85:1006.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/77)
78.  [Spangrude GJ, Johnson GR. Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci U S A 1990; 87:7433.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/78)
79.  [Udomsakdi C, Eaves CJ, Sutherland HJ, Lansdorp PM. Separation of functionally distinct subpopulations of primitive human hematopoietic cells using rhodamine-123. Exp Hematol 1991; 19:338.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/79)
80.  [Sun J, Ramos A, Chapman B, et al. Clonal dynamics of native haematopoiesis. Nature 2014; 514:322.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/80)
81.  [Busch K, Klapproth K, Barile M, et al. Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. Nature 2015; 518:542.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/81)
82.  [Notta F, Zandi S, Takayama N, et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science 2016; 351:aab2116.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/82)
83.  [Kirstetter P, Anderson K, Porse BT, et al. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 2006; 7:1048.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/83)
84.  [Scheller M, Huelsken J, Rosenbauer F, et al. Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol 2006; 7:1037.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/84)
85.  [Sugimura R, He XC, Venkatraman A, et al. Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell 2012; 150:351.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/85)
86.  [Zhang CC, Kaba M, Ge G, et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 2006; 12:240.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/86)
87.  [Kay HM. Hypothesis: How many cell-generations. Lancet 1965; 2:418.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/87)
88.  [Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A 1999; 96:3120.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/88)
89.  [Van Zant G, de Haan G, Rich IN. Alternatives to stem cell renewal from a developmental viewpoint. Exp Hematol 1997; 25:187.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/89)
90.  [Harrison DE, Stone M, Astle CM. Effects of transplantation on the primitive immunohematopoietic stem cell. J Exp Med 1990; 172:431.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/90)
91.  [Morrison SJ, Wandycz AM, Akashi K, et al. The aging of hematopoietic stem cells. Nat Med 1996; 2:1011.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/91)
92.  [Van Zant G, Holland BP, Eldridge PW, Chen JJ. Genotype-restricted growth and aging patterns in hematopoietic stem cell populations of allophenic mice. J Exp Med 1990; 171:1547.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/92)
93.  [Nijnik A, Woodbine L, Marchetti C, et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature 2007; 447:686.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/93)
94.  [TILL JE, MCCULLOCH EA, SIMINOVITCH L. A STOCHASTIC MODEL OF STEM CELL PROLIFERATION, BASED ON THE GROWTH OF SPLEEN COLONY-FORMING CELLS. Proc Natl Acad Sci U S A 1964; 51:29.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/94)
95.  [von Lindern M, Zauner W, Mellitzer G, et al. The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood 1999; 94:550.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/95)
96.  [Marley SB, Lewis JL, Gordon MY. Progenitor cells divide symmetrically to generate new colony-forming cells and clonal heterogeneity. Br J Haematol 2003; 121:643.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/96)
97.  [Curry JL, Trentin JJ. Hemopoietic spleen colony studies. I. Growth and differentiation. Dev Biol 1967; 15:395.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/97)
98.  [Gregory CJ, McCulloch EA, Till JE. Repressed growth of C57BL marrow in hybrid hosts reversed by antisera directed against non-H-2 alloantigens. Transplantation 1972; 13:138.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/98)
99.  [Suda T, Suda J, Ogawa M. Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors. Proc Natl Acad Sci U S A 1984; 81:2520.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/99)
100.  [Lansdorp PM, Dragowska W. Maintenance of hematopoiesis in serum-free bone marrow cultures involves sequential recruitment of quiescent progenitors. Exp Hematol 1993; 21:1321.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/100)
101.  [Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/101)
102.  [Shivdasani RA. Stem cell transcription factors. Hematol Oncol Clin North Am 1997; 11:1199.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/102)
103.  [Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90:489.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/103)
104.  [Metcalf D. Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation. Blood 1998; 92:345.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/104)
105.  [Enver T, Heyworth CM, Dexter TM. Do stem cells play dice? Blood 1998; 92:348.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/105)
106.  [Butler JS, Dent SY. The role of chromatin modifiers in normal and malignant hematopoiesis. Blood 2013; 121:3076.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/106)
107.  [Xu J, Shao Z, Glass K, et al. Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis. Dev Cell 2012; 23:796.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/107)
108.  [Beerman I, Bock C, Garrison BS, et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. Cell Stem Cell 2013; 12:413.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/108)
109.  [Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011; 44:23.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/109)
110.  [Kerenyi MA, Shao Z, Hsu YJ, et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife 2013; 2:e00633.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/110)
111.  [Stewart MH, Albert M, Sroczynska P, et al. The histone demethylase Jarid1b is required for hematopoietic stem cell self-renewal in mice. Blood 2015; 125:2075.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/111)
112.  [Ko M, Bandukwala HS, An J, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011; 108:14566.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/112)
113.  [Jeong M, Park HJ, Celik H, et al. Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. Cell Rep 2018; 23:1.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/113)
114.  [Loberg MA, Bell RK, Goodwin LO, et al. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia 2019; 33:1635.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/114)
115.  [Maryanovich M, Zahalka AH, Pierce H, et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. Nat Med 2018; 24:782.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/115)
116.  [Poulos MG, Ramalingam P, Gutkin MC, et al. Endothelial transplantation rejuvenates aged hematopoietic stem cell function. J Clin Invest 2017; 127:4163.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/116)
117.  [Tikhonova AN, Dolgalev I, Hu H, et al. The bone marrow microenvironment at single-cell resolution. Nature 2019; 569:222.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/117)
118.  [Morales-Mantilla DE, King KY. The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease. Curr Stem Cell Rep 2018; 4:264.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/118)
119.  [de Bruin AM, Libregts SF, Valkhof M, et al. IFNγ induces monopoiesis and inhibits neutrophil development during inflammation. Blood 2012; 119:1543.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/119)
120.  [Walkley CR, Shea JM, Sims NA, et al. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007; 129:1081.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/120)
121.  [Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007; 129:1097.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/121)
122.  [Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464:852.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/122)
123.  [Kode A, Manavalan JS, Mosialou I, et al. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 2014; 506:240.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/123)
124.  [Dong L, Yu WM, Zheng H, et al. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 2016; 539:304.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/124)
125.  [Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood 2017; 130:1693.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/125)
126.  [Verovskaya EV, Dellorusso PV, Passegué E. Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation. Trends Mol Med 2019; 25:494.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/126)
127.  [Leimkühler NB, Schneider RK. Inflammatory bone marrow microenvironment. Hematology Am Soc Hematol Educ Program 2019; 2019:294.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/127)
128.  [Pronk E, Raaijmakers MHGP. The mesenchymal niche in MDS. Blood 2019; 133:1031.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/128)
129.  [Batsivari A, Haltalli MLR, Passaro D, et al. Dynamic responses of the haematopoietic stem cell niche to diverse stresses. Nat Cell Biol 2020; 22:7.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/129)
130.  [Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978; 4:7.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/130)
131.  [Schofield R. The pluripotent stem cell. Clin Haematol 1979; 8:221.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/131)
132.  [Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425:836.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/132)
133.  [Stewart FM, Crittenden RB, Lowry PA, et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 1993; 81:2566.](https://www.uptodate.cn/contents/zh-Hans/overview-of-hematopoietic-stem-cells/abstract/133)